A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

NCT03516591 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

DRUG: AMV564 14-Day CIV

Sponsor

Amphivena Therapeutics, Inc.